LY-3023414
- Generic Name
- LY-3023414
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26N4O3
- CAS Number
- 1386874-06-1
- Unique Ingredient Identifier
- C88817F47Y
- Background
LY3023414 has been used in trials studying the treatment of Neoplasm, Solid Tumor, COLON CANCER, BREAST CANCER, and Advanced Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Phase 2
Active, not recruiting
- Conditions
- Ann Arbor Stage III Non-Hodgkin LymphomaRecurrent GliomaRecurrent HepatoblastomaRecurrent Langerhans Cell HistiocytosisRecurrent Malignant Solid NeoplasmRecurrent OsteosarcomaStage III Osteosarcoma AJCC v7Stage IV Soft Tissue Sarcoma AJCC v7Ann Arbor Stage IV Non-Hodgkin LymphomaRecurrent Malignant Germ Cell Tumor
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 18
- Registration Number
- NCT03213678
- Locations
- 🇺🇸
Valley Children's Hospital, Madera, California, United States
🇺🇸Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Phase 2
Recruiting
- Conditions
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionOther: Laboratory Biomarker AnalysisProcedure: Bone Marrow Aspiration and BiopsyDrug: Larotrectinib SulfateProcedure: Bone ScanProcedure: Mutation Carrier ScreeningOther: Pharmacological StudyProcedure: Computed TomographyDrug: OlaparibDrug: PalbociclibDrug: Selumetinib SulfateDrug: TipifarnibDrug: ErdafitinibDrug: TazemetostatDrug: SamotolisibDrug: EnsartinibDrug: VemurafenibDrug: UlixertinibProcedure: Magnetic Resonance ImagingDrug: SelpercatinibProcedure: Positron Emission TomographyProcedure: Radionuclide ImagingProcedure: X-Ray Imaging
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2316
- Registration Number
- NCT03155620
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸East Carolina University, Greenville, North Carolina, United States
🇺🇸Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath